---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-407696"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2026-09-29T20:45:42+00:00"
generated_at: "2026-10-12T13:51:54.313917+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Phathom starts patient screening in Phase 3 pHalcon-NERD-302 testing as-needed VOQUEZNA for Non-Erosive GERD

## Summary
- Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study of as-needed VOQUEZNA (vonoprazan) 10 mg in adults with Non-Erosive GERD.
- Topline results are expected in the first quarter of 2028; if successful, the study would support a regulatory submission for a VOQUEZNA label expansion.
- The trial is expected to enroll approximately 500 adults with heartburn at least four days per week at roughly 80 U.S. sites.
- After a four-week open-label run-in, patients are randomized 1:1 to VOQUEZNA 10 mg or placebo as-needed for 24 weeks, with the primary endpoint assessed at Week 12.

## SEC filing metadata
- accession: 0001193125-26-407696
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2026-09-29T20:45:42+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/0001193125-26-407696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-407696
- JSON: https://secwatch.observer/filing/0001193125-26-407696.json
- Plain text: https://secwatch.observer/filing/0001193125-26-407696.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.